Phase 3 Study, Exploratory, Disease Activity Controlled Dose Escalating Study to Assess the Efficacy, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Chronic Spontaneous Urticaria.
Phase of Trial: Phase III
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Bilastine (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Acronyms BUCSU
- 10 Jun 2017 Biomarkers information updated
- 25 May 2016 Status changed from recruiting to completed.
- 27 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 2 Jul 2015 to 1 Jun 2016.